“XELOX + Bevacizumab Compared to FOLFOX4 + Bevacizumab in First Line Metastatic Colorectal Cancer in a Non-Reimbursed Health Care System: A Cost Analysis”. Acta Medica Philippina, vol. 49, no. 2, June 2015, https://doi.org/10.47895/amp.v49i2.988.